Safety and Efficacy of Combined Treatment with Pegylated Interferon Alpha-2b and Ribavirin for HCV Genotype 4 in Children

Journal of Interferon and Cytokine Research

Volumn 36, Issue 1, 2016, Pages 1-8

  El Karaksy, Hanaa M ^a   Mogahed, Engy A ^a   El Raziky, Mona S ^a   Saleh, Doaa ^a   Besheer, Mahmoud ^a   Mubarak, Samah ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; GAMMA-GLUTAMYLTRANSFERASE, HUMAN; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADOLESCENT; ANEMIA; ANOREXIA; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHILD; CHILL; CHRONIC HEPATITIS C; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HAIR LOSS; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; INJECTION SITE REACTION; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; SIDE EFFECT; VIROLOGY; VIRUS LOAD; VOMITING; WEIGHT REDUCTION; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; GENOTYPE; GROWTH, DEVELOPMENT AND AGING; HEPACIVIRUS; HEPATITIS C, CHRONIC; IMMUNOLOGY; LEUKOCYTE COUNT; NEUTROPHIL; PATHOLOGY; PRESCHOOL CHILD; QUESTIONNAIRE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADOLESCENT; ANTIVIRAL AGENTS; BODY HEIGHT; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FEVER; GAMMA-GLUTAMYLTRANSFERASE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; LEUKOCYTE COUNT; MALE; NEUTROPENIA; NEUTROPHILS; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84954439464     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2015.0066     Document Type: Article

References (47)

1. Abdel-Aziz DH, Sabry NA, El-Sayed MH, El-Gazayerly ON. 2011. Efficacy and safety of pegylated interferon in children and adolescents infected with chronic hepatitis C. J Pharm Pract 24:203-210.
2. Abdel-Hady M, Bansal S, Davison SM, Brown M, Tizzard SA, Mulla S, Barnes E, Davies P, Mieli-Vergani G, Kelly DA. 2014. Treatment of chronic viral hepatitis C in children and adolescents. Arch Dis Child 99:505-510.
3. Abdel-Hady M, Bunn S, Sira J, Brown RM, Brundler MA, Davies P, Kelly DA. 2011. Chronic hepatitis C in childrenreview of natural history at a national centre. J Viral Hepat 18:535-540.
4. Abdel-Razek W, Waked I. 2015. Optimal therapy in genotype 4 chronic hepatitis C: finally cured? Liver Int 35:27-34.
5. Al Ali J, Owayed S, Al-Qabandi W, Husain K, Hasan F. 2010. Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents. Ann Hepatol 9:156-160.
6. Al-Huthail YR. 2006. Neuropsychiatric side-effects of interferon alfa therapy for hepatitis C and their management: A review. Saudi J Gastroenterol 12:59-67.
7. Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, Saadoun D, Soumelis V, Marcellin P. 2010. Hepatitis C: viral and host factors associated with non-response to PEGylated interferon plus ribavirin. Liver Int 30:1259-1269.
8. Baker RD, Dee D, Baker SS. 2007. Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C. J Clin Gastroenterol 41:111-114.
9. Cortez KJ, Kottilil S. 2015. Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. Ther Adv Chronic Dis 6:4-14.
10. Druyts E, Thorlund K, Wu P, Kanters S, Yaya S, Cooper CL, Mills EJ. 2013. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: A systematic review and meta-analysis. Clin Infect Dis 56:961-967.
11. El-Naghy S, Abdel-Ghaffar TY, El-Karaksy H, Abdel-Aty EF, El-Raziky M, Allam AA, Helmy H, El-Araby HA, Behairy BE, El-Guindy MA, El-Sebaie H, Abdel-Ghaffar AY, Ehsan NA, El-Hennawy AM, Zalata KR, Sira MM. 2014. Safety and efficacy of reiferon retard and ribavirin combination in chronic hepatitis C genotype 4 Egyptian children. World J Gastroenterol 20:4681-4691.
12. El-Raziky MS, El-Hawary M, Esmat G, Abouzied AM, El-Koofy N, Mohsen N, Mansour S, Shaheen A, Abdel Hamid M, El-Karaksy H. 2007. Prevalence and risk factors of asymptomatic hepatitis C virus infection in Egyptian children. World J Gastroenterol 13:1828-1832.
13. Esmat G, El Kassas M, Hassany M, Gamil M, El Raziky M. 2014. Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues. Liver Int 34:24-28.
14. Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Lö-schenberger K, Formann E, Staufer K, Steindl-Munda P. 2008. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1and 4 patients with rapid virological response. Gastroenterology 135:451-458.
15. Foster GR. 2009. Quality of life considerations for patients with chronic hepatitis C. J Viral Hepat 16:605-611.
16. Ghaffar TY, El Naghy S, El Sebaie H, El Monaiery M, Ghaffar AY. 2009. Pegylated alpha interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection. Indian J Pediatr 76:895-898.
17. Ghany MG, Strader DB, Thomas DL, Seef IL. 2009. Diagnosis, management and treatment of hepatitis C: an update. Hepatology 49:1335-1374.
18. Goodman ZD, Makhlouf HR, Liu L, Balistreri W, Gonzalez-Peralta RP, Haber B, Jonas MM, Mohan P, Molleston JP, Murray KF, Narkewicz MR, Rosenthal P, Smith LJ, Robuck PR, Schwarz KB. 2008. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology 47:836-843.
19. Guido M, Bortolotti F, Leandro G, Jara P, Hierro L, Larrauri J, Barbera C, Giacchino R, Zancan L, Balli F, Crivellaro C, Cristina E, Pucci A, Rugge M. 2003. Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time? Am J Gastroenterol 98:660-663.
20. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Jr., Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group. 2004. Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346-355.
21. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, Bernard MJ, Portmann G, Poulsen H, Scheuer PJ, Schmid M, Thaler H. 1995. Histological grading and staging of chronic hepatitis. J Hepatol 22:696-699.
22. Jara P, Hierro L, de la Vega A, Diaz C, Camarena C, Frauca E, Minos-Bartolo G, Díez-Dorado R, de Guevara CL, Larrauri J, Rueda M. 2008. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 27:142-148.
23. Kamal M. 2011. Hepatitis C virus genotype 4 therapy: progress and challenges. Liver Int 31:45-52.
24. Kamal SM. 2014. Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents. Hepat Med 6:61-77.
25. Kamal SM, Ahmed A, Mahmoud S, Nabegh L, El Gohary I, Obadan I, Hafez T, Ghoraba D, Aziz AA, Metaoei M. 2011. Enhanced efficacy of pegylated interferon alfa-2a plus ribavirin over pegylated interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C genotype 4: A randomized trial and health-related quality of life analysis. Liver Int 31:401-411.
26. Kamal SM, El Kamary SS, Shardell MD, Hashem M, Ahmed IN, Muhammadi M, Sayed K, Moustafa A, Hakem SA, Ibrahiem A, Moniem M, Mansour H, Abdelaziz M. 2007. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology 46:1732-1740.
27. Kamal SM, Nasser IA. 2008. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology 47:1371-1383.
28. Lo Re V, 3rd, Amorosa VK, Localio AR, O'Flynn R, Teal V, Dorey-Stein Z, Kostman JR, Gross R. 2009. Adherence to hepatitis C virus therapy and early virologic outcomes. Clin Infect Dis 48:186-193.
29. Lukasiewicz E, Gorfine M, Freedman LS, Pawlotsky JM, Schalm SW, Ferrari C, Zeuzem S, Neumann AU; DITTOHCV Study Group. 2010. Prediction of non SVR to therapy with PEGylated interferon-alpha 2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment. J Viral Hepat 17:345-351.
30. Mack CL, Gonzalez-Peralta RP, Gupta N, Leung D, Narkewicz MR, Roberts EA, Rosenthal P, Schwarz KB. 2012. NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr 54:838-855.
31. Mehta N, Murthy UK, Kaul V, Alpert S, Abruzzese G, Teitelbaum C. 2010. Outcome of retinopathy in chronic hepatitis C patients treated with peginterferon and ribavirin. Dig Dis Sci 55:452-457.
32. Miller FD, Abu-Raddad LJ. 2010. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci U S A 107:14757-14762.
33. Narkewicz MR, Rosenthal P, Schwarz KB, Drack A, Margolis T, Repka MX. 2010. Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon. J Pediatr Gastroenterol Nutr 51:183-186.
34. Rady NH, Darwish RK, Mogahed EA, Mandour IA, Abo Youssef H, Sharaf SA, El-Karaksy HM. 2015. Potential genetic markers for prediction of treatment response in Egyptian children infected with HCV genotype 4. Cytokine 75:349-355.
35. Reddy KR, Nelson DR, Zeuzem S. 2009. Ribavirin: current role in the optimal clinical management of chronic hepatitis C. J Hepatol 50:402-411.
36. Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, Schlecker C, Herrmann E, Lötsch J, Berg T. 2011. Importance of IL28B gene polymorphisms in HCV genotype 2 and 3 infected patients. J Hepatol 54:415-421.
37. Schwarz KB, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber BA, Jonas MM, Rosenthal P, Mohan P, Balistreri WF, Narkewicz MR, Smith L, Lobritto SJ, Rossi S, Valsamakis A, Goodman Z, Robuck PR, Barton BA. 2011. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 140:450-458.
38. Serranti D, Buonsense D, Ceccarelli M, Gargiullo L, Ranno O, Valentin P. 2011. Pediatric hepatitis C infection: to treat or not to treat. What's the best for the child? Eur Rev Med Pharmacol Sci 15:1057-1067.
39. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S. 2007. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 357:124-134.
40. Sokal EM, Bourgois A, Stéphenne X, Silveira T, Porta G, Gardovska D, Fischler B, Kelly D. 2010. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 52:827-831.
41. Standard Egyptian Growth. 2008. Diabetes Endocrine Metabolism Pediatric Unit Cairo University Children's Hospital. Available at http://dempuegypt.blogspot.com/. Accessed 10/ 6/2010.
42. Sung H, Chang M, Saab S. 2011. Management of hepatitis C antiviral therapy adverse effects. Curr Hepat Rep 10:33-40.
43. Umar M, Khan AG, Abbas Z, Arora S, Asifabbas N, Elewaut A, Esmat G, Foster G, Fried M, Goh KL, Hamama TB, Imawari M, Isakov V, Krabshuis J, LaBrecque D, Lemair A, Malfertheiner P, Ryder S, Schiedermaier P, Stimac D, Tandon R, Villamil F, Zapata R, Ferenci P. 2014. World Gastroenterology Organization global guidelines: diagnosis, management and prevention of hepatitis C April 2013. J Clin Gastroenterol 48:2014-2017.
44. Wantuck JM, Ahmed A, Nguyen MH. 2014. Review article: The epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther 39:137-174.
45. Welbourn S, Pause A. 2007. The hepatitis C virus NS2/3 protease. Curr Issues Mol Biol 9:63-69.
46. Wirth S, Pieper-Boustani H, Lang T, Ballauff A, Kullmer U, Gerner P, Wintermeyer P, Jenke A. 2005. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 41:1013-1018.
47. Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, Shelton M, Kerkar N, Galoppo M, Pedreira A, Rodriguez-Baez N, Ciocca M, Lachaux A, Lacaille F, Lang T, Kullmer U, Huber WD, Gonzalez T, Pollack H, Alonso E, Broue P, Ramakrishna J, Neigut D, Valle-Segarra AD, Hunter B, Goodman Z, Xu CR, Zheng H, Noviello S, Sniukiene V, Brass C, Albrecht JK. 2010. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 52:501-507.